Catalyst Wire Dossier Catalyst Wire Dossier

Salmeterol Xinafoate/Fluticasone Propionate Combination

salmeterol xinafoate and fluticasone propionate · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Salmeterol Xinafoate/Fluticasone Propionate Combination, covering 2013-07-11 to 2013-07-11. Get the full timeline:

Most recent: Clinical Trial Update: Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination [Phase 2]

See pricing